Welcome to our dedicated page for Phibro Animal news (Ticker: PAHC), a resource for investors and traders seeking the latest updates and insights on Phibro Animal stock.
Phibro Animal Health Corporation (Nasdaq: PAHC) is a diversified global animal health and nutrition company with operations across Animal Health, Mineral Nutrition, and Performance Products. This news page aggregates company-issued updates and other coverage related to PAHC stock, helping readers follow developments that Phibro discloses through press releases and regulatory communications.
Phibro’s news flow frequently includes financial results and guidance, such as quarterly and full-year earnings releases and updates to financial outlook for future fiscal years. These announcements often detail net sales by segment, trends in medicated feed additives (MFAs), nutritional specialty products, vaccines, mineral nutrition products, and performance products, as well as commentary on factors like product demand, foreign currency impacts, and operating expenses.
Investors can also expect corporate and strategic announcements, including information about acquisitions or portfolio additions, such as the referenced MFA portfolio acquired from Zoetis, Inc., and enterprise programs like Phibro Forward, which the company describes as focused on efficiency, growth, and cultural engagement. Leadership and governance updates, including planned executive transitions and matters presented at the annual meeting of stockholders, are typically communicated through press releases and accompanying SEC filings.
Product and pipeline-related news is another key category. Phibro has highlighted developments in companion animal oral health, including the licensing agreement with Lighthouse Pharmaceuticals, Inc. for a proprietary compound for canine periodontal care and the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease. Such releases describe product mechanisms, study results, and distribution plans.
In addition, Phibro issues dividend declarations, notices of participation in investor conferences, and details on upcoming webcasts and conference calls to discuss results. Readers interested in PAHC can use this page to monitor these recurring updates and review the company’s own descriptions of its performance, strategy, and product initiatives.
Phibro Animal Health (Nasdaq: PAHC) announced a planned leadership transition effective July 1, 2026. Jack Bendheim will move from CEO and President to Executive Chairman while remaining Board Chairman. Daniel (Dani) Bendheim will become Chief Executive Officer and President. Jack has led the company since 1969, served as President since 1988 and was CEO since March 2014. Dani joined in 1997 and has held roles including VP of Business Development, President of Performance Products, Executive VP Corporate Strategy and most recently Chief Transformation Officer overseeing the Phibro Forward initiative. The Board gave unanimous support and the full executive team will remain in place.
Phibro Animal Health (Nasdaq: PAHC) reported a strong start to fiscal 2026 for the quarter ended September 30, 2025, with net sales of $363.9M (up 40%) and net income $26.5M. Animal Health sales rose 55% to $283.5M driven by MFAs, nutritional specialties and vaccines. Adjusted EBITDA for the quarter was $61.9M and management raised FY2026 adjusted EBITDA guidance to $230M–$240M while maintaining net sales guidance of $1.43B–$1.48B. Balance sheet highlights include $749.1M total debt, 3.3x gross leverage and $85.3M cash and short-term investments.
Phibro Animal Health Corporation (Nasdaq: PAHC) declared a quarterly cash dividend of $0.12 per share on both Class A and Class B common stock. The dividend is payable on December 17, 2025 to stockholders of record at the close of business on November 26, 2025. The declaration was made by the Board of Directors in Teaneck, NJ.
Phibro Animal Health (NASDAQ:PAHC) announced the national launch of Restoris piezoelectric dental gel for dogs with periodontal disease on October 30, 2025. Restoris, developed with a U.S. dental school and licensed to Phibro, is applied into periodontal pockets, cured with supplied UV light, and uses piezoelectric particles to generate microcurrents that stimulate osteoblasts.
Clinical and laboratory studies showed significant reductions in periodontal pocket depth and generation of alveolar bone around the treated tooth within 30 days. Restoris is available for pre-order from Patterson Veterinary Supply and will ship within the next 30 days.
Phibro Animal Health (Nasdaq: PAHC) expects to announce its first quarter results on Wednesday, November 5, 2025 after market close. Management will host a conference call and webcast on Thursday, November 6, 2025 at 9:00 AM Eastern Time.
Investors can access the live presentation and slides at https://investors.pahc.com or dial +1 (888) 330-2022 (U.S./Canada) or +1 (365) 977-0051 (international) and provide conference ID 3927884. A replay of the webcast will be available approximately two hours after the live event at https://investors.pahc.com.
Phibro Animal Health (Nasdaq: PAHC) announced on October 9, 2025 an exclusive licensing agreement with Lighthouse Pharmaceuticals to develop, manufacture, and commercialize a proprietary compound for canine periodontal health. Phibro will lead global regulatory, commercial, and distribution efforts while Lighthouse advances its gingipain inhibitor platform. The compound has shown preclinical efficacy and safety. Financial terms were not disclosed. The collaboration targets improved veterinary periodontal care and potential long‑term benefits for dogs and companion animal portfolios.
Phibro Animal Health Corporation (Nasdaq: PAHC) announced its participation in the upcoming Morgan Stanley Annual Global Healthcare Conference. CFO Glenn David will present to financial analysts and investors on September 9, 2025, at 12:20 PM ET at the Sheraton New York Times Square Hotel.
The presentation will be accessible via live audio stream on the company's investor relations website, with a replay available for later viewing.
Phibro Animal Health (NASDAQ:PAHC) reported strong financial results for Q4 and fiscal year 2025, with significant growth across key metrics. The company achieved Q4 net sales of $378.7M (up 39%) and net income of $17.2M (up $16.5M), with diluted EPS of $0.42.
For FY2025, PAHC reported net sales of $1.29B (up 27%), net income of $48.3M, and adjusted EBITDA of $183.7M (up 65%). The growth was primarily driven by the successful integration of the Zoetis MFA portfolio and strong performance across Animal Health segments.
Looking ahead, PAHC provided FY2026 guidance with projected net sales of $1.43-1.48B and adjusted EBITDA of $225-235M, reflecting continued confidence in their growth trajectory.
Phibro Animal Health Corporation (Nasdaq: PAHC) has scheduled its fourth quarter and fiscal year 2025 financial results announcement for Wednesday, August 27, 2025, after market close. The company will host a conference call and webcast to discuss the results on Thursday, August 28, 2025, at 9:00 AM Eastern Time.
Investors can access the presentation through the company's investor relations website at https://investors.pahc.com or join via phone using the provided dial-in numbers. A replay of the webcast will be made available approximately two hours after the event concludes.
Phibro Animal Health Corporation (Nasdaq: PAHC) has announced a quarterly dividend declaration. The company's Board of Directors has approved a cash dividend of $0.12 per share for both Class A and Class B common stock. The dividend will be paid on September 24, 2025, to shareholders who are registered as of September 3, 2025.
FAQ
What is the current stock price of Phibro Animal (PAHC)?
What is the market cap of Phibro Animal (PAHC)?
